Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KFP-H018
- Development stage
- Phase 1
- Lead developer
- Nanjing Carephar Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
KFP-H018 is a selective, small-molecule inhibitor of Janus kinase 1 (JAK1) developed by Nanjing Carephar Pharmaceutical (also known as Jiangsu Carephar Pharmaceutical). It is designed to treat autoimmune diseases and potentially cancer by modulating the JAK-STAT signaling pathway, which is central to inflammatory cytokine signaling. Clinical development has included an oral formulation for rheumatoid arthritis and a topical ointment formulation for dermatological conditions, with Phase I trials evaluating safety, tolerability, and pharmacokinetics.
- Other names
- H018H-018H 018
02
Targets
Beyond the preview
Go deeper on KFP-H018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KFP-H018.